Alectinib

證據等級: L5

預測適應症: 10 個

Alectinib: From ALK-Positive Non-Small Cell Lung Cancer to ALK-Driven Rare Lung Tumors

One-Sentence Summary

Alectinib is a second-generation, highly selective ALK/RET tyrosine kinase inhibitor, with robust evidence supporting its use in ALK-positive non-small cell lung cancer (NSCLC) — approved in the United States, EU, and Japan, but not yet registered in New Zealand. The TxGNN model predicts it may be applicable to ALK-driven rare lung tumors (including neuroendocrine carcinomas), supported by 2 clinical trials (including an active Phase 2/3 UK basket trial) and multiple case reports documenting responses in molecularly-defined rare cancers. For the core indication of ALK-positive NSCLC, evidence reaches Level 1 from multiple completed Phase 3 RCTs — one of the strongest evidence bases in contemporary thoracic oncology.

Quick Overview

Item	Content
Original Indication	ALK-Positive Non-Small Cell Lung Cancer (approved in US/EU/Japan; not registered in New Zealand)
Predicted New Indication	ALK-Driven Rare Lung Tumors (Neuroendocrine Carcinoma)
TxGNN Prediction Score	99.95%
Evidence Level	L1 (ALK+ NSCLC overall); L3 (rare ALK+ lung tumors specifically)
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

While detailed mechanism of action data from DrugBank is pending retrieval (data gap DG002), alectinib is well established in the scientific literature as a second-generation, ATP-competitive inhibitor of anaplastic lymphoma kinase (ALK) and RET tyrosine kinases. It binds with high selectivity to the ALK kinase domain, blocking downstream proliferation signals through the RAS/MAPK, JAK/STAT3, and PI3K/AKT pathways. Compared to the first-generation ALK inhibitor crizotinib, alectinib demonstrates markedly superior central nervous system penetration and retains activity against multiple acquired resistance mutations (including L1196M, G1269A, and F1174L), which is why multiple Phase 3 trials have demonstrated its superiority.

The primary oncogenic driver targeted by alectinib — the EML4-ALK fusion gene — drives tumor growth through constitutive ALK signaling and is present in approximately 3–5% of all NSCLC cases globally. The mechanistic rationale for extending this to rare ALK-positive lung tumors is straightforward: wherever an ALK fusion acts as the dominant oncogenic driver, targeted ALK inhibition should produce clinical responses regardless of histological subtype. This "oncogene-agnostic" principle has been directly validated by multiple case reports demonstrating objective responses to alectinib in ALK-rearranged large cell neuroendocrine carcinoma (LCNEC), atypical pulmonary carcinoids, and combined neuroendocrine-adenocarcinoma tumors.

The DETERMINE basket trial (NCT05770037) directly operationalizes this hypothesis — a Phase 2/3 UK platform trial actively recruiting adults, pediatric, and TYA patients with ALK-positive rare cancers across tumor histologies. Although an earlier dedicated Phase 2 trial (NCT04644315) was terminated due to recruitment challenges (only 1 patient enrolled), DETERMINE's pooled rare-population design overcomes this limitation. From a New Zealand perspective, the most urgent finding is that alectinib is unregistered despite Level 1 evidence in ALK+ NSCLC, representing both an unmet clinical need and a concrete regulatory opportunity.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05770037	Phase 2/3	Recruiting	30	DETERMINE basket trial (UK): evaluates alectinib in adult, pediatric, and TYA patients with ALK-positive rare cancers across tumor types including neuroendocrine malignancies; alectinib arm designed to assess efficacy in molecularly-defined rare cancers beyond NSCLC; completion expected October 2029
NCT04644315	Phase 2	Terminated	1	Home-based, open-label study of alectinib in locally advanced or metastatic ALK-positive solid tumors other than lung cancer; terminated early due to insufficient enrollment, illustrating the recruitment challenge in this rare population

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38598794	2024	Phase 3 RCT	N Engl J Med	ALINA trial: adjuvant alectinib vs platinum-based chemotherapy in resected ALK+ NSCLC; significant improvement in disease-free survival, establishing adjuvant use
28586279	2017	Phase 3 RCT	N Engl J Med	ALEX trial: alectinib vs crizotinib in untreated advanced ALK+ NSCLC; alectinib superior in PFS and CNS activity
28501140	2017	Phase 3 RCT	Lancet	J-ALEX trial: alectinib vs crizotinib in Japanese patients; median PFS 34.1 vs 10.2 months favouring alectinib
30981696	2019	Phase 3 RCT	Lancet Respir Med	ALESIA trial: alectinib vs crizotinib in Asian ALK+ NSCLC; consistent PFS benefit in Asian populations confirms generalisability
38331773	2024	Systematic Review / Network Meta-analysis	BMC Cancer	Comparative efficacy of all ALK inhibitors for global and Asian patients; alectinib identified as an optimal first-line option
29151522	2018	Case Report	Internal Medicine (Tokyo)	ALK-rearranged large cell neuroendocrine carcinoma (LCNEC) with hepatic and bone metastases; significant partial response to alectinib after failure of cytotoxic chemotherapy
34994612	2021	Case Report	JCO Precision Oncology	Metastatic ALK-fusion-positive LCNEC; partial response to alectinib documented, supporting ALK-agnostic treatment approach
37031440	2023	Case Report	Orvosi Hetilap	Mixed large cell neuroendocrine carcinoma of the lung with ALK fusion; alectinib used as targeted therapy alternative to cytostatics with favourable initial response
36690569	2023	Case Report	Clin Lung Cancer	ALK-positive neuroendocrine lung tumour; favorable response to alectinib, adding to the growing body of ALK+ neuroendocrine case evidence
37561984	2023	Review	JCO Precision Oncology	ALK inhibitors (including alectinib and crizotinib) in adult-onset neuroblastoma; ALK somatic mutations enriched in adult disease; review supports ALK-inhibitor rationale across ALK-driven tumour types

New Zealand Market Information

Alectinib currently has no Medsafe-approved products in New Zealand (0 licenses as of 2026-06-06). The drug is approved in the United States (FDA, brand name Alecensa®), the European Union (EMA), Japan (PMDA), and numerous other jurisdictions for ALK-positive NSCLC in both first-line metastatic and adjuvant settings. New Zealand patients currently lack registered access to this standard-of-care agent.

Cytotoxicity

Alectinib is an antineoplastic agent used in the targeted treatment of ALK-positive lung cancer.

Item	Content
Cytotoxicity Classification	Targeted therapy — Second-generation ALK/RET tyrosine kinase inhibitor (non-conventional cytotoxic)
Myelosuppression Risk	Low to Moderate — anaemia is the most common haematologic adverse event (including rare haemolytic anaemia); neutropenia and thrombocytopenia are less frequent than with conventional cytotoxics
Emetogenicity Classification	Low
Monitoring Items	Full blood count with differential; liver function tests (ALT/AST — hepatotoxicity monitoring); creatine phosphokinase (CPK — myalgia/rhabdomyolysis risk); fasting lipid panel (hypertriglyceridaemia); blood glucose; ECG (sinus bradycardia); body weight (clinically significant weight gain in ~10% of patients)
Handling Protection	Follow institutional cytotoxic drug handling protocols; oral capsule formulation reduces compounding exposure compared to IV agents, but standard cytotoxic precautions apply for handling and disposal

Safety Considerations

Based on published literature (New Zealand package insert data not available due to absence of Medsafe registration):

Metabolic toxicity: Life-threatening hypertriglyceridaemia-induced pancreatitis has been reported; fasting lipid monitoring is warranted, particularly in patients with pre-existing dyslipidaemia
Weight gain: Clinically significant weight gain observed in approximately 10% of patients on long-term alectinib; aetiology involves metabolic effects and potential promotion of adipogenesis; baseline weight and longitudinal monitoring recommended
Bradycardia: Sinus bradycardia is documented; QTc prolongation risk appears low based on intensive electrocardiographic monitoring in pivotal Phase 2 studies
Haematologic: Haemolytic anaemia has been reported as a rare but serious adverse event; monitoring of CBC and haemolysis markers (LDH, bilirubin, reticulocyte count) is advisable
Dermatologic: Erythema multiforme and DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome have been reported; most cases were managed with dose modification or corticosteroids, with successful rechallenge in some cases

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Alectinib has Level 1 evidence from at least four Phase 3 RCTs (ALEX, J-ALEX, ALESIA, ALINA) confirming superiority over crizotinib in ALK-positive NSCLC across global, Asian, and adjuvant populations. Despite this, alectinib holds zero Medsafe registrations in New Zealand — a clear and actionable gap between global standard of care and New Zealand clinical access. The novel repurposing direction toward ALK-driven rare lung tumors (neuroendocrine carcinomas) is mechanistically sound and supported by an active Phase 2/3 basket trial and accumulating case evidence, but requires more prospective data before regulatory consideration.

To proceed, the following is needed:

Immediate priority: Submit Medsafe registration application for ALK-positive NSCLC based on existing global Phase 3 data (ALEX/J-ALEX/ALESIA/ALINA trials); expedited pathway may be applicable given overseas approvals
Retrieve mechanism of action data from DrugBank API to complete DG002 data gap
Develop New Zealand-specific safety monitoring protocol covering hepatic, cardiac (bradycardia), metabolic (hypertriglyceridaemia, weight gain), and haematologic surveillance
Confirm ALK testing capacity and companion diagnostic availability (e.g., Ventana D5F3 IHC or FISH) across New Zealand oncology centres
Conduct pharmacoeconomic evaluation for PHARMAC funding consideration, including cost-effectiveness against lorlatinib (third-generation ALK inhibitor) and reference to Australian PBS listing if available
For rare tumour repurposing: await interim data from the DETERMINE basket trial (NCT05770037; expected 2025–2026) before initiating a New Zealand regulatory pathway for this novel indication
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.